EC-Naprosyn (naproxen delayed-release tablets)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
- Patients at greatest risk of this reaction are those taking………..or angiotensin receptor blockers (ARBs),
Advanced Renal Disease
- ...and patients should be adequately hydrated.